Advertisement
New Zealand markets closed

  • NZX 50

    11,682.39
    -89.42 (-0.76%)
     

  • NZD/USD

    0.6127
    +0.0006 (+0.09%)
     

  • NZD/EUR

    0.5713
    -0.0001 (-0.02%)
     

  • ALL ORDS

    8,031.90
    +19.80 (+0.25%)
     

  • ASX 200

    7,789.90
    +20.50 (+0.26%)
     

  • OIL

    82.34
    +0.17 (+0.21%)
     

  • GOLD

    2,377.40
    +8.40 (+0.35%)
     

  • NASDAQ

    19,752.30
    -156.56 (-0.79%)
     

  • FTSE

    8,272.46
    +67.35 (+0.82%)
     

  • Dow Jones

    39,134.76
    +299.90 (+0.77%)
     

  • DAX

    18,254.18
    +186.27 (+1.03%)
     

  • Hang Seng

    18,076.44
    -258.88 (-1.41%)
     

  • NIKKEI 225

    38,589.72
    -43.30 (-0.11%)
     

  • NZD/JPY

    97.3810
    +0.1610 (+0.17%)
     

Agenus Announces Virtual Annual Shareholders Meeting

Business Wire
·1-min read

LEXINGTON, Mass., June 04, 2024--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Tuesday, June 11, 2024

ADVERTISEMENT

Time: 10:30 a.m. ET

A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2024.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604262147/en/

Contacts

Investor
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com